• レポートコード:TPM-NV154 • 出版社/出版日:Transparency Market Research / 2019年10月28日 • レポート形態:英文、PDF、211ページ • 納品方法:Eメール • 産業分類:医療 |
Single User | ¥857,660 (USD5,795) | ▷ お問い合わせ |
Multi User | ¥1,301,660 (USD8,795) | ▷ お問い合わせ |
Global Site License | ¥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、全身性エリテマトーデス治療の世界市場について調べ、全身性エリテマトーデス治療の世界市場規模、市場動向、市場シェア、市場環境、市場予測、薬物別(抗マラリア薬(クロロキンおよびヒドロクロロキン)、非ステロイド系抗炎症薬(NSAIDS)(イブプロフェン、ナプロキセン、およびその他)、コルチコステロイド(プレドニゾン、ヒドロコルチゾン、デキサメタゾン、およびその他)、免疫抑制薬(アザチオプリン、シクロトレキサミド、シクロトホスファミド、 およびその他]、その他(生物製剤、B細胞モジュレーターなど))分析、デリバリー方法別(静脈内、皮下、および経口)分析、流通チャンネル別(病院薬局、小売薬局、およびオンライン販売)分析、関連企業情報などをまとめました。 ・全身性エリテマトーデス治療の市場概要 ・全身性エリテマトーデス治療の市場動向 ・全身性エリテマトーデス治療の世界市場規模・予測 ・全身性エリテマトーデス治療市場:薬物別(抗マラリア薬(クロロキンおよびヒドロクロロキン)、非ステロイド系抗炎症薬(NSAIDS)(イブプロフェン、ナプロキセン、およびその他)、コルチコステロイド(プレドニゾン、ヒドロコルチゾン、デキサメタゾン、およびその他)、免疫抑制薬(アザチオプリン、シクロトレキサミド、シクロトホスファミド、 およびその他]、その他(生物製剤、B細胞モジュレーターなど)) ・全身性エリテマトーデス治療市場:デリバリー方法別(静脈内、皮下、および経口) ・全身性エリテマトーデス治療市場:デリバリー方法別(静脈内、皮下、および経口) ・地域別分析(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米) ・競争環境・関連企業分析 |
Although healthcare companies in the systemic lupus erythematosus treatment market have made significant advances regarding drug development, certain side effects of these drugs are anticipated to negatively influence market growth. For instance, immunosuppressive drugs are estimated to reach a value of ~US$ 1.5 billion by 2027, and continue to dominate the systemic lupus erythematosus treatment market throughout the forecast period. However, enduring disease activity with recurring flare ups and accumulating toxicity due to glucocorticoids (GC) and immunosuppressive (IS) medications are some of the side effects associated with SLE drugs.
Since SLE is a heterogeneous disease of varying severity, healthcare companies in the systemic lupus erythematosus treatment landscape are beginning to understand that, developing ‘one size fits all’ immunosuppressive drugs increases the burden of symptoms in patients. This is why, healthcare companies in the systemic lupus erythematosus treatment market are adopting the ‘treat-to-target’ approach to develop drugs that effectively manage and minimize the incidence of disease activity. Healthcare providers are implementing patient-tailored therapeutic strategies with the introduction of improved biologic agents.
レポート目次1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions
2.2. Research Methodology
3. Executive Summary
3.1. Global Systemic Lupus Erythematosus Treatment Market Snapshot
4. Market Overview
4.1. Product Overview
4.2. Key Industry Events
4.3. Market Dynamics
4.3.1. Drivers and Restraints Snapshot Analysis
4.3.2. Drivers
4.3.3. Restraints
4.3.4. Opportunities
4.4. Global Systemic Lupus Erythematosus Treatment Market Revenue Projection
4.5. Global Systemic Lupus Erythematosus Treatment Market Outlook
5. Market Outlook
5.1. Key Mergers & Acquisitions
5.2. Pipeline Analysis
5.3. Disease Prevalence & Incidence Rate Globally with Key Countries
6. Global Systemic Lupus Erythematosus Treatment Market Analysis, by Drug
6.1. Introduction
6.2. Global Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Drug
6.3. Global Systemic Lupus Erythematosus Treatment Market Forecast, by Drug
6.3.1. Antimalarial Drugs
6.3.1.1. Chloroquine
6.3.1.2. Hydrochloroquine
6.3.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
6.3.2.1. Ibuprofen
6.3.2.2. Naproxen
6.3.2.3. Others
6.3.3. Corticosteroids
6.3.3.1. Prednisone
6.3.3.2. Hydrocortisone
6.3.3.3. Dexamethasone
6.3.3.4. Others
6.3.4. Immunosuppressive Drugs
6.3.4.1. Azathioprine
6.3.4.2. Cyclophosphamide
6.3.4.3. Methotrexate
6.3.4.4. Others
6.3.5. Others (Biologics, B-cell Modulators, etc.)
7. Global Systemic Lupus Erythematosus Treatment Market Analysis, by Mode of Delivery
7.1. Introduction
7.2. Global Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Mode of Delivery
7.3. Global Systemic Lupus Erythematosus Treatment Market Forecast, by Mode of Delivery
7.3.1. Intravenous
7.3.2. Subcutaneous
7.3.3. Oral
7.4. Global Systemic Lupus Erythematosus Treatment Market Analysis, by Mode of Delivery
8. Global Systemic Lupus Erythematosus Treatment Market Analysis, by Distribution Channel
8.1. Introduction
8.2. Global Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
8.3. Global Systemic Lupus Erythematosus Treatment Market Forecast, by Distribution Channel
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Sales
8.4. Global Systemic Lupus Erythematosus Treatment Market Analysis, by Distribution Channel
9. Global Systemic Lupus Erythematosus Treatment Market Analysis, by Region
9.1. Global Systemic Lupus Erythematosus Treatment Market Scenario, by Country
9.2. Global Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Region
9.3. Global Systemic Lupus Erythematosus Treatment Market Forecast, by Region
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
10. North America Systemic Lupus Erythematosus Treatment Market Analysis
10.1. Key Findings
10.2. North America Systemic Lupus Erythematosus Treatment Market Overview
10.3. North America Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Country
10.4. North America Systemic Lupus Erythematosus Treatment Market Forecast, by Country
10.4.1. U.S.
10.4.2. Canada
10.5. North America Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Drug
10.6. North America Systemic Lupus Erythematosus Treatment Market Forecast, by Drug
10.6.1. Antimalarial Drugs
10.6.1.1. Chloroquine
10.6.1.2. Hydrochloroquine
10.6.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
10.6.2.1. Ibuprofen
10.6.2.2. Naproxen
10.6.2.3. Others
10.6.3. Corticosteroids
10.6.3.1. Prednisone
10.6.3.2. Hydrocortisone
10.6.3.3. Dexamethasone
10.6.3.4. Others
10.6.4. Immunosuppressive Drugs
10.6.4.1. Azathioprine
10.6.4.2. Cyclophosphamide
10.6.4.3. Methotrexate
10.6.4.4. Others
10.6.5. Others (Biologics, B-cell Modulators, etc.)
10.7. North America Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery
10.8. North America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery
10.8.1. Intravenous
10.8.2. Subcutaneous
10.8.3. Oral
10.9. North America Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
10.10. North America Systemic Lupus Erythematosus Treatment Market Forecast, by Distribution Channel
10.10.1. Hospital Pharmacies
10.10.2. Retail Pharmacies
10.10.3. Online Sales
11. Europe Systemic Lupus Erythematosus Treatment Market Analysis
11.1. Key Findings
11.2. Europe Systemic Lupus Erythematosus Treatment Market Overview
11.3. Europe Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.4. Europe Systemic Lupus Erythematosus Treatment Market Forecast, by Country/Sub-region
11.4.1. Germany
11.4.2. U.K.
11.4.3. France
11.4.4. Spain
11.4.5. Italy
11.4.6. Rest of Europe
11.5. Europe Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Drug
11.6. Europe Systemic Lupus Erythematosus Treatment Market Forecast, by Drug
11.6.1. Antimalarial Drugs
11.6.1.1. Chloroquine
11.6.1.2. Hydrochloroquine
11.6.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
11.6.2.1. Ibuprofen
11.6.2.2. Naproxen
11.6.2.3. Others
11.6.3. Corticosteroids
11.6.3.1. Prednisone
11.6.3.2. Hydrocortisone
11.6.3.3. Dexamethasone
11.6.3.4. Others
11.6.4. Immunosuppressive Drugs
11.6.4.1. Azathioprine
11.6.4.2. Cyclophosphamide
11.6.4.3. Methotrexate
11.6.4.4. Others
11.6.5. Others (Biologics, B-cell Modulators, etc.)
11.7. Europe Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery
11.8. Europe Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery
11.8.1. Intravenous
11.8.2. Subcutaneous
11.8.3. Oral
11.9. Europe Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
11.10. Europe Systemic Lupus Erythematosus Treatment Market Forecast, by Distribution Channel
11.10.1. Hospital Pharmacies
11.10.2. Retail Pharmacies
11.10.3. Online Sales
12. Asia Pacific Systemic Lupus Erythematosus Treatment Market Analysis
12.1. Key Findings
12.2. Asia Pacific Systemic Lupus Erythematosus Treatment Market Overview
12.3. Asia Pacific Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.4. Asia Pacific Systemic Lupus Erythematosus Treatment Market Forecast, by Country/Sub-region
12.4.1. Japan
12.4.2. China
12.4.3. India
12.4.4. Australia & New Zealand
12.4.5. Rest of Asia Pacific
12.5. Asia Pacific Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Drug
12.6. Asia Pacific Systemic Lupus Erythematosus Treatment Market Forecast, by Drug
12.6.1. Antimalarial Drugs
12.6.1.1. Chloroquine
12.6.1.2. Hydrochloroquine
12.6.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
12.6.2.1. Ibuprofen
12.6.2.2. Naproxen
12.6.2.3. Others
12.6.3. Corticosteroids
12.6.3.1. Prednisone
12.6.3.2. Hydrocortisone
12.6.3.3. Dexamethasone
12.6.3.4. Others
12.6.4. Immunosuppressive Drugs
12.6.4.1. Azathioprine
12.6.4.2. Cyclophosphamide
12.6.4.3. Methotrexate
12.6.4.4. Others
12.6.5. Others (Biologics, B-cell Modulators, etc.)
12.7. Asia Pacific Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery
12.8. Asia Pacific Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery
12.8.1. Intravenous
12.8.2. Subcutaneous
12.8.3. Oral
12.9. Asia Pacific Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
12.10. Asia Pacific Systemic Lupus Erythematosus Treatment Market Forecast, by Distribution Channel
12.10.1. Hospital Pharmacies
12.10.2. Retail Pharmacies
12.10.3. Online Sales
13. Latin America Systemic Lupus Erythematosus Treatment Market Analysis
13.1. Key Findings
13.2. Latin America Systemic Lupus Erythematosus Treatment Market Overview
13.3. Latin America Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.4. Latin America Systemic Lupus Erythematosus Treatment Market Forecast, by Country/Sub-region
13.4.1. Brazil
13.4.2. Mexico
13.4.3. Rest of Latin America
13.5. Latin America Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Drug
13.6. Latin America Systemic Lupus Erythematosus Treatment Market Forecast, by Drug
13.6.1. Antimalarial Drugs
13.6.1.1. Chloroquine
13.6.1.2. Hydrochloroquine
13.6.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
13.6.2.1. Ibuprofen
13.6.2.2. Naproxen
13.6.2.3. Others
13.6.3. Corticosteroids
13.6.3.1. Prednisone
13.6.3.2. Hydrocortisone
13.6.3.3. Dexamethasone
13.6.3.4. Others
13.6.4. Immunosuppressive Drugs
13.6.4.1. Azathioprine
13.6.4.2. Cyclophosphamide
13.6.4.3. Methotrexate
13.6.4.4. Others
13.6.5. Others (Biologics, B-cell Modulators, etc.)
13.7. Latin America Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery
13.8. Latin America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery
13.8.1. Intravenous
13.8.2. Subcutaneous
13.8.3. Oral
13.9. Latin America Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
13.10. Latin America Systemic Lupus Erythematosus Treatment Market Forecast, by Distribution Channel
13.10.1. Hospital Pharmacies
13.10.2. Retail Pharmacies
13.10.3. Online Sales
14. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Overview
14.3. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
14.4. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Forecast, by Country/Sub-region
14.4.1. GCC Countries
14.4.2. South Africa
14.4.3. Rest of Middle East & Africa
14.5. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Drug
14.6. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Forecast, by Drug
14.6.1. Antimalarial Drugs
14.6.1.1. Chloroquine
14.6.1.2. Hydrochloroquine
14.6.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
14.6.2.1. Ibuprofen
14.6.2.2. Naproxen
14.6.2.3. Others
14.6.3. Corticosteroids
14.6.3.1. Prednisone
14.6.3.2. Hydrocortisone
14.6.3.3. Dexamethasone
14.6.3.4. Others
14.6.4. Immunosuppressive Drugs
14.6.4.1. Azathioprine
14.6.4.2. Cyclophosphamide
14.6.4.3. Methotrexate
14.6.4.4. Others
14.6.5. Others (Biologics, B-cell Modulators, etc.)
14.7. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery
14.8. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery
14.8.1. Intravenous
14.8.2. Subcutaneous
14.8.3. Oral
14.9. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
14.10. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Forecast, by Distribution Channel
14.10.1. Hospital Pharmacies
14.10.2. Retail Pharmacies
14.10.3. Online Sales
15. Competitive Landscape
15.1. Competition Matrix
15.2. Company Profile
15.2.1. GlaxoSmithKline plc
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Financial Overview
15.2.1.3. Product Portfolio
15.2.1.4. SWOT Analysis
15.2.1.5. Strategic Overview
15.2.2. F. Hoffmann-La Roche Ltd.
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Financial Overview
15.2.2.3. Product Portfolio
15.2.2.4. SWOT Analysis
15.2.2.5. Strategic Overview
15.2.3. Pfizer, Inc.
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Financial Overview
15.2.3.3. Product Portfolio
15.2.3.4. SWOT Analysis
15.2.3.5. Strategic Overview
15.2.4. AstraZeneca plc
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Financial Overview
15.2.4.3. Product Portfolio
15.2.4.4. SWOT Analysis
15.2.4.5. Strategic Overview
15.2.5. Merck & Co., Inc.
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Financial Overview
15.2.5.3. Product Portfolio
15.2.5.4. SWOT Analysis
15.2.5.5. Strategic Overview
15.2.6. Bristol-Myers Squibb Company
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Financial Overview
15.2.6.3. Product Portfolio
15.2.6.4. SWOT Analysis
15.2.6.5. Strategic Overview
15.2.7. Anthera Pharmaceuticals, Inc.
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Financial Overview
15.2.7.3. Product Portfolio
15.2.7.4. SWOT Analysis
15.2.7.5. Strategic Overview
15.2.8. ImmuPharma PLC
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Product Portfolio
15.2.8.3. SWOT Analysis
15.2.8.4. Strategic Overview
15.2.9. Aurinia Pharmaceuticals, Inc.
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Product Portfolio
15.2.9.3. SWOT Analysis
15.2.9.4. Strategic Overview